Karla McHughes
Payments from drug & device makers
Across 865 payments — averaging $63.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$34K
- Mannkind Corporation$4K
- AstraZeneca$2K
- Sanofi-aventis U.S. LLC$2K
- Amgen$1K
- Lilly USA, LLC$1K
- plus $9K from 49 others
What the payments were for
- Consulting fees$5,23110%
- Speaking & faculty fees$26,78049%
- Travel & lodging$4,7349%
- Food & beverage$17,81333%
- Education$1310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$54,689 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 139 | $215,611 |
| MounjaroTirzepatide | 166 | $203,866 |
| JardianceEmpagliflozin | 67 | $89,754 |
| FarxigaDapagliflozin Propanediol | 108 | $89,621 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $49,668 |
| TrulicityDulaglutide | 23 | $46,318 |
| Xigduo XrDapaglifloz Propaned/Metformin | 22 | $27,995 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $27,966 |
| VascepaIcosapent Ethyl | 33 | $26,663 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 20 | $23,693 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $21,215 |
| SynthroidLevothyroxine Sodium | 176 | $19,256 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $17,470 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $15,338 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $14,981 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,350 | $250,183189 claims |
| Novo NordiskOzempic | $34,492 | $215,611139 claims |
| Boehringer IngelheimJardiance | $715 | $89,75467 claims |
| AstraZenecaFarxiga | $2,330 | $89,621108 claims |
| AbbVieSynthroid | $521 | $19,256176 claims |
| MerckJanumet Xr | $189 | $15,33814 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $226 | $2,952181 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Allen
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.